{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:15Z","timestamp":1792320375513,"version":"4.4.0"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The pharmacokinetics of multiple-dose linezolid were determined following administration of five 600-mg oral doses given every 12 h to each of six healthy male volunteers. Concentrations of the drug were determined in plasma and inflammatory blister fluid using high-pressure liquid chromatography. A mean peak concentration in plasma of 18.3 \u03bcg\/ml (standard deviation [SD], 6.0) was attained at a mean time of 0.7 h (SD, 0.3) after the final dose. The penetration into the inflammatory fluid was 104% (SD, 20.7). A mean peak concentration of 16.4 \u03bcg\/ml (SD, 10.6) was attained in the inflammatory fluid at 3 h (SD, 0.6) after the final dose. The elimination half-life from serum and inflammatory fluid was 4.9 (SD, 1.8) and 5.7 (SD, 1.7) h, respectively. The area under the concentration-time curve in plasma and blister fluid was 140.3 (SD, 73.1) and 155.3 (SD, 80.1) \u03bcg \u00b7 h\/ml, respectively. These data suggest that linezolid has good tissue penetration, and we can predict that it will be successful in the treatment of a variety of gram-positive infections.<\/jats:p>","DOI":"10.1128\/aac.45.6.1843-1846.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"1843-1846","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":174,"title":["Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses"],"prefix":"10.1128","volume":"45","author":[{"given":"Thekli","family":"Gee","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ellis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Marshall","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Andrews","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ashby","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wise","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Microbiology, City Hospital NHS Trust, Birmingham, B18 7QH, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"435","article-title":"Oxazolidinones: a new class of antimicrobials.","volume":"16","author":"Ford C.","year":"1999","unstructured":"Ford C. Hamel J. Stapert D. Moerman J. Hutchinson H. Barbachyn M. Zurenko G. Oxazolidinones: a new class of antimicrobials. Infect. Med. 16 1999 435 445","journal-title":"Infect. Med."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1508"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-199528020-00005","article-title":"The importance of pharmacokinetic\/pharmacodynamic surrogate markers of outcome. Focus on antibacterial agents.","volume":"28","author":"Hyatt J. M.","year":"1995","unstructured":"Hyatt J. M. McKinnon P. S. Zimmer G. S. Schentag J. J. The importance of pharmacokinetic\/pharmacodynamic surrogate markers of outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28 1995 143 160","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/00912709922011962","article-title":"A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam.","volume":"39","author":"Lasher-Sisson T.","year":"1999","unstructured":"Lasher-Sisson T. Jungbluth G. Hopkins N. K. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J. Clin. Pharmacol. 39 1999 1277 1282","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.1039"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/j.1552-4604.1988.tb05740.x","article-title":"The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.","volume":"28","author":"Nix D. E.","year":"1988","unstructured":"Nix D. E. Schentag J. J. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol. 28 1988 169 178","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_3_2_9_2","first-page":"1050","article-title":"Mathematical examination of dual individualization principles. I Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin and tobramycin.","volume":"25","author":"Schentag J. J.","year":"1991","unstructured":"Schentag J. J. Nix D. E. Adelman M. H. Mathematical examination of dual individualization principles. I Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin and tobramycin. DICP Ann. Pharmacother. 25 1991 1050 1057","journal-title":"DICP Ann. Pharmacother."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1791"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/infdis\/142.1.77","article-title":"The influence of protein binding upon tissue fluid levels of six \u03b2-lactam antibiotics.","volume":"142","author":"Wise R.","year":"1980","unstructured":"Wise R. Gillett A. P. Cadge B. Durham R. Baker S. The influence of protein binding upon tissue fluid levels of six \u03b2-lactam antibiotics. J. Infect. Dis. 142 1980 77 82","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/42.6.721","article-title":"The in-vitro activity of linezolid (U-100766) and tentative breakpoints.","volume":"42","author":"Wise R.","year":"1998","unstructured":"Wise R. Andrews J. M. Boswell F. J. Ashby J. P. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J. Antimicrob. Chemother. 42 1998 721 728","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12968\/hosp.2000.61.1.1268","article-title":"Clinical efficacy and antimicrobial pharmacodynamics.","volume":"61","author":"Wise R.","year":"2000","unstructured":"Wise R. Clinical efficacy and antimicrobial pharmacodynamics. Hosp. Med. 61 2000 24 30","journal-title":"Hosp. Med."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.839"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.6.1843-1846.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.6.1843-1846.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:14:17Z","timestamp":1645463657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.6.1843-1846.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1128\/AAC.45.6.1843-1846.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.6.1843-1846.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2000-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}